Leukemia, Promyelocytic, Acute - 25 Studies Found
Recruiting |
: Proteasome Inhibition in Acute Promyelocytic Leukemia : Relapsed Acute Promyelocytic Leukemia : 2013-09-22 : Drug: Bortezomib Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute prom |
Recruiting |
: Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia : Acute Promyelocytic Leukemia : 2007-08-16 : Drug: Single agent arsenic trioxide duration of maintenance therapy, 6 months versus 12 months |
Recruiting |
: Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia : Acute Promyelocytic Leukemia : 2008-05-07 : Drug: NRX 195183 Soft Gelatin Capsule Daily oral NRX 195183 administration for 90 days to assess CR rate |
Recruiting |
: Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia : Acute Promyelocytic Leukemia : 2016-02-11 :
|
Terminated |
: Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia : Acute Promyelocytic Leukemia : 2009-09-25 :
|
Recruiting |
: French Registry of First-line Treatment of Acute Promyelocytic Leukemia : Acute Promyelocytic Leukemia : 2016-09-22 |
Completed |
: Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia : Acute Promyelocytic Leukemia : 2013-03-28 : Other: Health Related Quality of Life (HRQOL) measures Other Names:
|
Withdrawn |
: New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia : Acute Promyelocytic Leukemia : 2008-04-28 :
|
Active, not recruiting |
: Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy : Acute Promyelocytic Leukemia : 2011-07-27 : Drug: Tretinoin and Arsenic Trioxide See Detailed Description |
Recruiting |
: Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia : Acute Promyelocytic Leukemia : 2016-03-02 |